Analysts Expect Novartis AG (NYSE:NVS) Will Post Earnings of $1.64 Per Share


Share on StockTwits

Analysts expect Novartis AG (NYSE:NVS) to report $1.64 earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Novartis’ earnings. Novartis reported earnings per share of $1.55 in the same quarter last year, which would suggest a positive year-over-year growth rate of 5.8%. The business is scheduled to report its next earnings report before the market opens on Tuesday, April 27th.

On average, analysts expect that Novartis will report full year earnings of $6.44 per share for the current fiscal year, with EPS estimates ranging from $6.35 to $6.55. For the next fiscal year, analysts expect that the company will report earnings of $6.88 per share, with EPS estimates ranging from $6.71 to $7.09. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Novartis.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Monday, January 25th. The company reported $1.34 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.37 by ($0.03). The company had revenue of $12.77 billion during the quarter, compared to analyst estimates of $12.86 billion. Novartis had a net margin of 14.71% and a return on equity of 24.39%. The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.32 EPS.

Several equities analysts have issued reports on the company. Sanford C. Bernstein started coverage on Novartis in a research report on Monday, March 22nd. They set a “market perform” rating on the stock. Argus restated a “hold” rating on shares of Novartis in a report on Tuesday, March 16th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Novartis in a research report on Friday, January 15th. They set a “buy” rating on the stock. Societe Generale reissued a “buy” rating on shares of Novartis in a report on Tuesday, March 23rd. Finally, Morgan Stanley reissued an “overweight” rating on shares of Novartis in a report on Tuesday, February 2nd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. Novartis currently has a consensus rating of “Hold” and a consensus target price of $108.50.

A number of institutional investors have recently bought and sold shares of NVS. AXA S.A. acquired a new position in Novartis in the third quarter worth approximately $134,000. UBS Asset Management Americas Inc. acquired a new position in Novartis in the third quarter worth approximately $517,000. ExodusPoint Capital Management LP acquired a new position in Novartis in the 3rd quarter worth approximately $1,417,000. First City Capital Management Inc. boosted its stake in Novartis by 79.5% in the 3rd quarter. First City Capital Management Inc. now owns 10,163 shares of the company’s stock worth $889,000 after purchasing an additional 4,501 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in Novartis in the 3rd quarter worth approximately $1,453,000. Hedge funds and other institutional investors own 9.86% of the company’s stock.

NYSE NVS opened at $86.30 on Thursday. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.49. The business’s 50 day moving average is $86.31 and its two-hundred day moving average is $88.58. Novartis has a 12-month low of $77.04 and a 12-month high of $98.52. The stock has a market capitalization of $197.51 billion, a price-to-earnings ratio of 27.93, a PEG ratio of 1.76 and a beta of 0.59.

The business also recently disclosed an annual dividend, which was paid on Monday, March 15th. Investors of record on Friday, March 5th were paid a dividend of $3.3784 per share. This represents a dividend yield of 2.2%. The ex-dividend date was Thursday, March 4th. This is a positive change from Novartis’s previous annual dividend of $3.04. Novartis’s dividend payout ratio (DPR) is currently 39.69%.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.

See Also: Hedge Funds

Get a free copy of the Zacks research report on Novartis (NVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.